Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
J Am Coll Cardiol. 2011 Aug 23;58(9):907-14. doi: 10.1016/j.jacc.2011.05.023.
The aim of this study was to evaluate the association between calculated creatinine clearance (CCC)-based contrast dose and renal complications in patients undergoing percutaneous coronary interventions (PCI).
Excess volumes of contrast media are associated with renal complications in patients undergoing cardiac procedures. Because contrast media are excreted by the kidney, we hypothesized that a dose estimation on the basis of CCC would provide a simple strategy to define a safe dose of contrast media.
We assessed the association between CCC-based contrast dose and the risk of contrast-induced nephropathy (CIN) and need for in-hospital dialysis in 58,957 patients undergoing PCI and enrolled in the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) registry from 2007 to 2008. Patients receiving dialysis at the time of the procedure were excluded.
The risk of CIN and nephropathy requiring dialysis (NRD) was directly associated with increasing contrast volume adjusted for renal function. The risk for CIN and NRD approached significance when the ratio of contrast dose/CCC exceeded 2 (adjusted odds ratio [OR] for CIN: 1.16, 95% confidence interval [CI]: 0.98 to 1.37, adjusted OR for NRD: 1.72, 95% CI: 0.9 to 3.27) and was dramatically elevated in patients exceeding a contrast to CCC ratio of 3 (adjusted OR for CIN: 1.46, 95% CI: 1.27 to 1.66, adjusted OR for NRD: 1.89, 95% CI: 1.21 to 2.94).
Our study supports the need for minimizing contrast dose in patients with renal dysfunction. A contrast dose on the basis of estimated renal function with a planned contrast volume restricted to less than thrice and preferably twice the CCC might be valuable in reducing the risk of CIN and NRD.
本研究旨在评估经皮冠状动脉介入治疗(PCI)患者中基于计算肌酐清除率(CCC)的造影剂剂量与肾脏并发症之间的关系。
在接受心脏手术的患者中,造影剂的过量使用与肾脏并发症相关。由于造影剂是通过肾脏排泄的,我们假设基于 CCC 的剂量估计可以提供一种简单的策略来确定造影剂的安全剂量。
我们评估了 2007 年至 2008 年在 BMC2(密歇根蓝十字蓝盾心血管联合会)注册中心接受 PCI 且未在手术时接受透析的 58957 例患者中基于 CCC 的造影剂量与造影剂诱导肾病(CIN)和住院透析需求风险之间的关系。排除在手术时接受透析的患者。
CIN 和需要透析的肾病(NRD)的风险与肾功能调整后的造影剂体积呈直接相关。当造影剂量/CCC 比值超过 2 时,CIN 和 NRD 的风险接近显著(CIN 的校正比值比 [OR]:1.16,95%置信区间 [CI]:0.98 至 1.37;NRD 的校正 OR:1.72,95% CI:0.9 至 3.27),在造影剂/CCC 比值超过 3 的患者中,风险显著升高(CIN 的校正 OR:1.46,95% CI:1.27 至 1.66;NRD 的校正 OR:1.89,95% CI:1.21 至 2.94)。
我们的研究支持在肾功能障碍患者中尽量减少造影剂剂量的需要。基于估计肾功能的造影剂量,计划造影剂体积限制在 CCC 的三倍以下,最好是两倍以下,可能有助于降低 CIN 和 NRD 的风险。